– PRIMROSE 1 and PRIMROSE 2, pivotal Phase 3 clinical trials to assess efficacy and safety of novel oral GnRH…
Category: Press release
The press releases from ObsEva
ObsEva SA to Attend Needham Annual Healthcare Conference in NYC
Geneva, Switzerland – 24 March 2017 – ObsEva SA (Nasdaq: OBSV), a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics for…
ObsEva to Present Pharmacology Results Demonstrating OBE022 Exerts a Synergistic Effect in Combination with Standard of Care in Animal Model for Preterm Labor
– OBE022 is ObsEva’s potential first-in-class, oral and selective PGF2alpha receptor antagonist – Geneva, Switzerland – 17 March 2017 – ObsEva SA (Nasdaq: OBSV), a Swiss biopharmaceutical company…
ObsEva Starts Phase 3 Clinical Program for Nolasiban in ART
– IMPLANT2 study to confirm efficacy and safety of novel, oral oxytocin receptor antagonist in infertile patients undergoing embryo transfer…
ObsEva SA to Attend LEERINK Partners Global Healthcare Conference in NYC
Geneva, Switzerland – February 03, 2017 – ObsEva SA (ObsEva) announced today that Ernest LOUMAYE, M.D., Ph.D., CEO and Co-Founder and Tim ADAMS, CFO, will…
ObsEva SA Announces Pricing of Initial Public Offering
(GLOBE NEWSWIRE via COMTEX) –ObsEva SA / ObsEva SA Announces Pricing of Initial Public Offering . Processed and transmitted by…
ObsEva Expands Leadership Team and Board of Directors with Industry Veterans
Geneva, Switzerland, 17 January 2017 – ObsEva SA (ObsEva), a biopharmaceutical company focused on the development and commercialization of novel therapeutics…
ObsEva Announces Completion of Phase 1 First-in-Women Study of OBE022 for the Treatment of Preterm Labor
– First-in-class orally active prostaglandin F2α receptor antagonist designed to safely control inflammation, uterine contractions, membrane ruptures and cervical changes that…
ObsEva Announces Results of the IMPLANT Phase 2 Trial of OBE001 (nolasiban) for the Improvement of Pregnancy and Live Birth Rates Following IVF/ICSI
Trial shows meaningful increase in pregnancy and live birth rates in patients treated with OBE001 ObsEva to proceed with a…
ObsEva Announces Plans to Conduct Initial Public Offering in the United States
GENEVA, SWITZERLAND, 17 October, 2016 – ObsEva SA, a Swiss biopharmaceutical company focused on the development and commercialization of novel…